Abstract
An estimated 4.5 million South Africans, mainly in settings of rural poverty, are in need of treatment for urogenital schistosomiasis. In spite of severe morbidity and mortality, schistosomiasis remains a neglected disease with an important gender impact. The World Health Organization recommends regular mass treatment of all school-aged children. In areas endemic for schistosomiasis children are treated with a single dose of praziquantel, used for almost 30 years as the drug of choice. If administered in childhood, praziquantel has been proven to effectively prevent schistosomiasis-related morbidity, as well as reduce the socio-economic impact of the disease. Moreover, preventing urogenital schistosomiasis may also reduce HIV transmission in sexually active females. In this paper we examine the impact of the disease, the use of generic praziquantel and the need for a change in health and drug policy in order to make generic praziquantel available for mass treatment campaigns in South Africa. Generic prazi...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Southern African Journal of Epidemiology and Infection
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
